Targeting the RB-E2F pathway in breast cancer

Oncogene

Volumn 35, Issue 37, 2016, Pages 4829-4835

  Johnson, J ^a   Thijssen, B ^a   McDermott, U ^b   Garnett, M ^b   Wessels, L F A ^a   Bernards, R ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE RB E2F; UNCLASSIFIED DRUG; AROMATASE INHIBITOR; CDK6 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; PALBOCICLIB; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE; RB1 PROTEIN, HUMAN; RETINOBLASTOMA BINDING PROTEIN; TRANSCRIPTION FACTOR E2F; UBIQUITIN PROTEIN LIGASE;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; TREATMENT RESPONSE; TUMOR DIFFERENTIATION; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; FEMALE; GENETICS; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY;

AROMATASE INHIBITORS; BREAST NEOPLASMS; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; E2F TRANSCRIPTION FACTORS; FEMALE; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIDINES; RETINOBLASTOMA BINDING PROTEINS; UBIQUITIN-PROTEIN LIGASES;

EID: 84959218324     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2016.32     Document Type: Review

References (66)

1. Baker SJ, Reddy EP. CDK4: a key player in the cell cycle, development, cancer. Genes Cancer 2012; 3: 658-669.
2. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009; 9: 153-166.
3. Chen HZ, Tsai SY, Leone G. Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat Rev Cancer 2009; 9: 785-797.
4. Chong JL, Wenzel PL, Saenz-Robles MT, Nair V, Ferrey A, Hagan JP et al. E2f1-3 switch from activators in progenitor cells to repressors in differentiating cells. Nature 2009; 462: 930-934.
5. Liu H, Tang X, Srivastava A, Pecot T, Daniel P, Hemmelgarn B et al. Redeployment of Myc and E2f1-3 drives Rb-deficient cell cycles. Nat Cell Biol 2015; 17: 1036-1048.
6. Sadasivam S, DeCaprio JA. The DREAM complex: master coordinator of cell cycle-dependent gene expression. Nat Rev Cancer 2013; 13: 585-595.
7. Yamasaki L, Jacks T, Bronson R, Goillot E, Harlow E, Dyson NJ. Tumor induction and tissue atrophy in mice lacking E2F-1. Cell 1996; 85: 537-548.
8. Rowland BD, Denissov SG, Douma S, Stunnenberg HG, Bernards R, Peeper DS. E2F transcriptional repressor complexes are critical downstream targets of p19 (ARF)/p53-induced proliferative arrest. Cancer Cell 2002; 2: 55-65.
9. Berthet C, Aleem E, Coppola V, Tessarollo L, Kaldis P. Cdk2 knockout mice are viable. Curr Biol 2003; 13: 1775-1785.
10. Berthet C, Klarmann KD, Hilton MB, Suh HC, Keller JR, Kiyokawa H et al. Combined loss of Cdk2 and Cdk4 results in embryonic lethality and Rb hypophosphorylation. Dev Cell 2006; 10: 563-573.
11. Malumbres M, Sotillo R, Santamaria D, Galan J, Cerezo A, Ortega S et al. Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell 2004; 118: 493-504.
12. Ortega S, Prieto I, Odajima J, Martin A, Dubus P, Sotillo R et al. Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat Genet 2003; 35: 25-31.
13. Santamaria D, Barriere C, Cerqueira A, Hunt S, Tardy C, Newton K et al. Cdk1 is sufficient to drive the mammalian cell cycle. Nature 2007; 448: 811-815.
14. Bernards R, Weinberg RA. A progression puzzle. Nature 2002; 418: 823.
15. Yoon SO, Shin S, Mercurio AM. Ras stimulation of E2F activity and a consequent E2F regulation of integrin alpha6beta4 promote the invasion of breast carcinoma cells. Cancer Res 2006; 66: 6288-6295.
16. Sage J. The retinoblastoma tumor suppressor and stem cell biology. Genes Dev 2012; 26: 1409-1420.
17. Arima Y, Hayashi H, Sasaki M, Hosonaga M, Goto TM, Chiyoda T et al. Induction of ZEB proteins by inactivation of RB protein is key determinant of mesenchymal phenotype of breast cancer. J Biol Chem 2012; 287: 7896-7906.
18. Johnson JL, Pillai S, Pernazza D, Sebti SM, Lawrence NJ, Chellappan SP. Regulation of matrix metalloproteinase genes by E2F transcription factors: Rb-Raf-1 interaction as a novel target for metastatic disease. Cancer Res 2012; 72: 516-526.
19. Pillai S, Trevino J, Rawal B, Singh S, Kovacs M, Li X et al. Beta-arrestin-1 mediates nicotine-induced metastasis through E2F1 target genes that modulate epithelial-mesenchymal transition. Cancer Res 2015; 75: 1009-1020.
20. Witkiewicz AK, Cox DW, Rivadeneira D, Ertel AE, Fortina P, Schwartz GF et al. The retinoblastoma tumor suppressor pathway modulates the invasiveness of ErbB2-positive breast cancer. Oncogene 2014; 33: 3980-3991.
21. Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, Nguyen DX et al. Genes that mediate breast cancer metastasis to the brain. Nature 2009; 459: 1005-1009.
22. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003; 3: 537-549.
23. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD et al. Genes that mediate breast cancer metastasis to lung. Nature 2005; 436: 518-524.
24. Fujiwara K, Yuwanita I, Hollern DP,rechek ER. Prediction and genetic demonstration of a role for activator E2Fs in Myc-induced tumors. Cancer Res 2011; 71: 1924-1932.
25. Opavsky R, Tsai SY, Guimond M, Arora A, Opavska J, Becknell B et al. Specific tumor suppressor function for E2F2 in Myc-induced T cell lymphomagenesis. Proc Natl Acad Sci USA 2007; 104: 15400-15405.
26. Yuwanita I, Barnes D, Monterey MD, O'Reilly S,rechek ER. Increased metastasis with loss of E2F2 in Myc-driven tumors. Oncotarget 2015; 6: 38210-38224.
27. Fluck MM, Schaffhausen BS. Lessons in signaling and tumorigenesis from polyomavirus middle T antigen. Microbiol Mol Biol Rev 2009; 73: 542-563; Table of contents.
28. Hollern DP, Honeysett J, Cardiff RD,rechek ER. The E2F transcription factors regulate tumor development and metastasis in a mouse model of metastatic breast cancer. Mol Cell Biol 2014; 34: 3229-3243.
29. Wu L, de Bruin A, Wang H, Simmons T, Cleghorn W, Goldenberg LE et al. Selective roles of E2Fs for ErbB2-and Myc-mediated mammary tumorigenesis. Oncogene 2015; 34: 119-128.
30. Andrechek ER. HER2/Neu tumorigenesis and metastasis is regulated by E2F activator transcription factors. Oncogene 2015; 34: 217-225.
31. Trikha P, Sharma N, Pena C, Reyes A, Pecot T, Khurshid S et al. E2f3 in tumor macrophages promotes lung metastasis. Oncogene 2016; 35: 3636-3646.
32. Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol 2011; 5: 5-23.
33. Ye X, Weinberg RA. Epithelial-mesenchymal plasticity: a central regulator of cancer progression. Trends Cell Biol 2015; 25: 675-686.
34. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006; 439: 353-357.
35. Gatza ML, Lucas JE, Barry WT, Kim JW, Wang Q, Crawford MD et al. A pathwaybased classification of human breast cancer. Proc Natl Acad Sci USA 2010; 107: 6994-6999.
36. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-536.
37. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW et al. A geneexpression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999-2009.
38. West M, Blanchette C, Dressman H, Huang E, Ishida S, Spang R et al. Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci USA 2001; 98: 11462-11467.
39. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 2008; 40: 499-507.
40. Niida A, Smith AD, Imoto S, Tsutsumi S, Aburatani H, Zhang MQ et al. Integrative bioinformatics analysis of transcriptional regulatory programs in breast cancer cells. BMC Bioinform 2008; 9: 404.
41. Niida A, Smith AD, Imoto S, Aburatani H, Zhang MQ, Akiyama T. Gene set-based module discovery in the breast cancer transcriptome. BMC Bioinform 2009; 10: 71.
42. Tian S, Roepman P, Van't Veer LJ, Bernards R, de Snoo F, Glas AM. Biological functions of the genes in the mammaprint breast cancer profile reflect the hallmarks of cancer. Biomarker Insights 2010; 5: 129-138.
43. Huang L, Zhao S, Frasor JM, Dai Y. An integrated bioinformatics approach identifies elevated cyclin E2 expression and E2F activity as distinct features of tamoxifen resistant breast tumors. PloS One 2011; 6: e22274.
44. Chanrion M, Negre V, Fontaine H, Salvetat N, Bibeau F, Mac Grogan G et al. A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer. Clin Cancer Res 2008; 14: 1744-1752.
45. Loi S, Piccart M, Sotiriou C. The use of gene-expression profiling to better understand the clinical heterogeneity of estrogen receptor positive breast cancers and tamoxifen response. Crit Rev Oncol Hematol 2007; 61: 187-194.
46. Loi S, Haibe-Kains B, Desmedt C, Wirapati P, Lallemand F, Tutt AM et al. Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics 2008; 9: 239.
47. Lin X, Li J, Yin G, Zhao Q, Elias D, Lykkesfeldt AE et al. Integrative analyses of gene expression and DNA methylation profiles in breast cancer cell line models of tamoxifen-resistance indicate a potential role of cells with stem-like properties. Breast Cancer Res 2013; 15: R119.
48. Zhu M, Liu CC, Cheng C. REACTIN: regulatory activity inference of transcription factors underlying human diseases with application to breast cancer. BMC Genomics 2013; 14: 504.
49. Khaleel SS,rews EH, Ung M, DiRenzo J, Cheng C. E2F4 regulatory program predicts patient survival prognosis in breast cancer. Breast Cancer Res 2014; 16: 486.
50. Rakha EA, Pinder SE, Paish EC, Robertson JF, Ellis IO. Expression of E2F-4 in invasive breast carcinomas is associated with poor prognosis. J Pathol 2004; 203: 754-761.
51. Thomassen M, Tan Q, Kruse TA. Gene expression meta-analysis identifies metastatic pathways and transcription factors in breast cancer. BMC Cancer 2008; 8: 394.
52. Singh S, Johnson J, Chellappan S. Small molecule regulators of Rb-E2F pathway as modulators of transcription. Biochim Biophys Acta 2010; 1799: 788-794.
53. Bose P, Simmons GL, Grant S. Cyclin-dependent kinase inhibitor therapy for hematologic malignancies. Exp Opin Investig Drugs 2013; 22: 723-738.
54. Cai D, Latham Jr VM, Zhang X, Shapiro GI. Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells. Cancer Res 2006; 66: 9270-9280.
55. Canduri F, Perez PC, Caceres RA, de Azevedo WF Jr. CDK9 a potential target for drug development. Med Chem 2008; 4: 210-218.
56. Vandenbosch R, Borgs L, Beukelaers P, Foidart A, Nguyen L, Moonen G et al. CDK2 is dispensable for adult hippocampal neurogenesis. Cell Cycle 2007; 6: 3065-3069.
57. Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO et al. The cyclindependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 2015; 16: 25-35.
58. Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 2004; 3: 1427-1438.
59. Toogood PL, Harvey PJ, Repine JT, Sheehan DJ, VanderWel SN, Zhou H et al. Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. J Med Chem 2005; 48: 2388-2406.
60. Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res 2009; 11: R77
61. Sabbah M, Courilleau D, Mester J, Redeuilh G. Estrogen induction of the cyclin D1 promoter: involvement of a cAMP response-like element. Proc Natl Acad Sci USA 1999; 96: 11217-11222.
62. Dickson MA. Molecular pathways: CDK4 inhibitors for cancer therapy. Clin Cancer Res 2014; 20: 3379-3383.
63. Vora SR, Juric D, Kim N, Mino-Kenudson M, Huynh T, Costa C et al. CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors. Cancer Cell 2014; 26: 136-149.
64. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917-921.
65. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012; 483: 100-103.
66. Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. GISTIC2. 0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol 2011; 12: R41.